These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 24885437)

  • 1. Comparing the effect of clopidogrel versus ticagrelor on coronary microvascular dysfunction in acute coronary syndrome patients (TIME trial): study protocol for a randomized controlled trial.
    Park SD; Baek YS; Woo SI; Kim SH; Shin SH; Kim DH; Kwan J; Park KS
    Trials; 2014 May; 15():151. PubMed ID: 24885437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
    Kunadian V; James SK; Wojdyla DM; Zorkun C; Wu J; Storey RF; Steg PG; Katus H; Emanuelsson H; Horrow J; Maya J; Wallentin L; Harrington RA; Gibson CM
    JACC Cardiovasc Interv; 2013 Jul; 6(7):671-83. PubMed ID: 23866179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the Effects of Ticagrelor and Clopidogrel on Microvascular Dysfunction in Patients With Acute Coronary Syndrome Using Invasive Physiologic Indices.
    Park K; Cho YR; Park JS; Park TH; Kim MH; Kim YD
    Circ Cardiovasc Interv; 2019 Oct; 12(10):e008105. PubMed ID: 31554423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PRotective Effect on the coronary microcirculation of patients with DIabetes by Clopidogrel or Ticagrelor (PREDICT): study rationale and design. A randomized multicenter clinical trial using intracoronary multimodal physiology.
    Cerrato E; Quirós A; Echavarría-Pinto M; Mejia-Renteria H; Aldazabal A; Ryan N; Gonzalo N; Jimenez-Quevedo P; Nombela-Franco L; Salinas P; Núñez-Gil IJ; Rumoroso JR; Fernández-Ortiz A; Macaya C; Escaned J
    Cardiovasc Diabetol; 2017 May; 16(1):68. PubMed ID: 28526024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomised trial to compare a protective effect of Clopidogrel Versus TIcagrelor on coronary Microvascular injury in ST-segment Elevation myocardial infarction (CV-TIME trial).
    Park SD; Lee MJ; Baek YS; Kwon SW; Shin SH; Woo SI; Kim DH; Kwan J; Park KS
    EuroIntervention; 2016 Oct; 12(8):e964-e971. PubMed ID: 27721212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
    Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and Rationale for comParison Between ticagreLor and clopidogrEl on mIcrocirculation in Patients with Acute cOronary Syndrome Undergoing Percutaneous Coronary Intervention (PLEIO) Trial.
    Park K; Cho YR; Park JS; Park TH; Kim MH; Kim YD
    J Cardiovasc Transl Res; 2018 Feb; 11(1):42-49. PubMed ID: 29344840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison between ticagrelor and clopidogrel on myocardial blood flow in patients with acute coronary syndrome, using 13 N-ammonia positron emission tomography.
    Jeong YJ; Park K; Kim YD
    Am Heart J; 2020 Apr; 222():121-130. PubMed ID: 32028138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome.
    Abergel E; Nikolsky E
    Vasc Health Risk Manag; 2010 Oct; 6():963-77. PubMed ID: 21057581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the Effects of Ticagrelor and Clopidogrel on Inflammatory Factors, Vascular Endothelium Functions and Short-Term Prognosis in Patients with Acute ST-Segment Elevation Myocardial Infarction Undergoing Emergency Percutaneous Coronary Intervention: a Pilot Study.
    Gao CZ; Ma QQ; Wu J; Liu R; Wang F; Bai J; Yang XJ; Fu Q; Wei P
    Cell Physiol Biochem; 2018; 48(1):385-396. PubMed ID: 30016801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized Trial Comparing the Effects of Ticagrelor Versus Clopidogrel on Myocardial Perfusion in Patients With Coronary Artery Disease.
    Pelletier-Galarneau M; Hunter CRRN; Ascah KJ; Beanlands RSB; Dwivedi G; deKemp RA; Chow BJW; Ruddy TD
    J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28465300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiplatelet Therapy in ACS Patients: Comparing Appropriate P2Y12 Inhibition by Clopidogrel to the Use of New P2Y12 Inhibitors.
    Ristorto J; Messas N; Marchandot B; Kibler M; Hess S; Meyer N; Schaeffer M; Tuzin N; Ohlmann P; Jesel L; Morel O
    J Atheroscler Thromb; 2018 Aug; 25(8):674-689. PubMed ID: 29415954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The REFLO-STEMI trial comparing intracoronary adenosine, sodium nitroprusside and standard therapy for the attenuation of infarct size and microvascular obstruction during primary percutaneous coronary intervention: study protocol for a randomised controlled trial.
    Nazir SA; Khan JN; Mahmoud IZ; Greenwood JP; Blackman DJ; Kunadian V; Been M; Abrams KR; Wilcox R; Adgey AA; McCann GP; Gershlick AH
    Trials; 2014 Sep; 15():371. PubMed ID: 25252600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention.
    Sweeny JM; Angiolillo DJ; Franchi F; Rollini F; Waksman R; Raveendran G; Dangas G; Khan ND; Carlson GF; Zhao Y; Teng R; Mehran R
    J Am Heart Assoc; 2017 Mar; 6(4):. PubMed ID: 28356282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Ticagrelor Versus Clopidogrel on Coronary Microvascular Function After Non-ST-Segment-Elevation Acute Coronary Syndrome.
    Xu J; Lo S; Mussap CJ; French JK; Rajaratnam R; Kadappu K; Premawardhana U; Nguyen P; Juergens CP; Leung DY
    Circ Cardiovasc Interv; 2022 Apr; 15(4):e011419. PubMed ID: 35369712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the reduction in myocardial infarctions in the PLATO trial: which patients benefited on ticagrelor vs. clopidogrel?
    DiNicolantonio JJ; Serebruany VL
    Int J Cardiol; 2013 May; 165(3):396-7. PubMed ID: 23273339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of clopidogrel, prasugrel and ticagrelor on endothelial function, inflammatory and oxidative stress parameters and platelet function in patients undergoing coronary artery stenting for an acute coronary syndrome. A randomised, prospective, controlled study.
    Schnorbus B; Daiber A; Jurk K; Warnke S; König J; Krahn U; Lackner K; Munzel T; Gori T
    BMJ Open; 2014 May; 4(5):e005268. PubMed ID: 24801283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ticagrelor vs clopidogrel followed by ticagrelor re-loading in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A randomized, pharmacodynamic comparison.
    Alexopoulos D; Kontoprias K; Gkizas V; Karanikas S; Ziakas A; Barampoutis N; Tsigkas G; Koutsogiannis N; Davlouros P; Patsilinakos S; Karvounis H; Hahalis G; Xanthopoulou I
    Platelets; 2016 Jul; 27(5):420-6. PubMed ID: 26763727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reducing Microvascular Dysfunction in Revascularized Patients with ST-Elevation Myocardial Infarction by Off-Target Properties of Ticagrelor versus Prasugrel. Rationale and Design of the REDUCE-MVI Study.
    Janssens GN; van Leeuwen MAH; van der Hoeven NW; de Waard GA; Nijveldt R; Diletti R; Zijlstra F; von Birgelen C; Escaned J; Valgimigli M; van Royen N
    J Cardiovasc Transl Res; 2016 Jun; 9(3):249-256. PubMed ID: 27102290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial.
    Lindholm D; Varenhorst C; Cannon CP; Harrington RA; Himmelmann A; Maya J; Husted S; Steg PG; Cornel JH; Storey RF; Stevens SR; Wallentin L; James SK
    Eur Heart J; 2014 Aug; 35(31):2083-93. PubMed ID: 24727884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.